Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen (AMGN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- AMGN trades near $385 with upcoming Q2 2026 earnings expected on August 4, following Q1 revenue growth of 6% to $8.6 billion and consistent earnings beats.
- BIIB closed recently around $203 after reporting Q2 revenue of $2.74 billion (up 3.4% year-over-year) and non-GAAP EPS well above estimates, with mixed stock reactions including gains of nearly 6% on one session.
- Both companies operate in the biotechnology sector, but AMGN offers broader product diversification and a dividend yield of approximately 2.6%, while BIIB focuses on neuroscience with recent emphasis on Alzheimer’s pipeline updates.
- Recent market activity shows BIIB exhibiting higher volatility tied to clinical and earnings developments, contrasted with AMGN’s steadier positioning ahead of its report.
- Sector exposure remains similar for both, with sentiment influenced by pipeline progress, regulatory developments, and overall biotech market conditions in recent weeks.
Introduction
Amgen Inc. (AMGN) and Biogen Inc. (BIIB) represent two established biotechnology companies whose stocks attract attention from investors seeking exposure to innovative therapies in areas such as oncology, inflammation, and neuroscience. This comparison examines their recent performance, business profiles, and market positioning to assist portfolio managers, swing traders, and long-term holders evaluating relative opportunities within the healthcare sector. The analysis draws on verifiable developments from the past several weeks to highlight contrasts in momentum, risk profiles, and catalysts without forecasting future outcomes.
Amgen Overview and Recent Performance
Amgen develops and commercializes biologic medicines targeting serious illnesses, with key products spanning oncology, cardiovascular disease, and bone health. In recent market activity, the stock has traded near $385 following Q1 2026 results that showed total revenues rising 6% to $8.6 billion, driven by volume growth. The company maintains a dividend yield near 2.6% and a relatively low beta, reflecting defensive characteristics within the sector. Ahead of its Q2 2026 earnings release scheduled for August 4, investor focus centers on product sales trends and any updates to full-year guidance. Sentiment in recent weeks has remained measured, supported by the firm’s history of earnings beats and diversified revenue base.
Biogen Overview and Recent Performance
Biogen specializes in therapies for neurological and neurodegenerative conditions, including multiple sclerosis and Alzheimer’s disease research. Recent performance reflects Q2 2026 results with revenue of $2.74 billion, up 3.4% year-over-year, and non-GAAP earnings per share exceeding consensus estimates. The stock has shown volatility, including sessions with gains exceeding 5% linked to earnings optimism, alongside earlier pressure from clinical data releases. Year-to-date returns stand around 12.6%, with a one-year gain near 52%. Market sentiment in recent weeks has been shaped by pipeline developments and broader biotech rotation, contributing to fluctuating price action around the $200 level.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed to operate across thousands of tickers. While hundreds of bots exist with varying strategies, timeframes, and performance statistics, only those demonstrating strong alignment with prevailing market conditions appear in the Trending AI Robots section. Available bots cover a wide range of metrics, including win rates, drawdowns, and trade frequency, allowing users to review detailed statistics before engagement. All bots employ distinct approaches suited to different market environments. For additional details on currently featured options, visit the Trending AI Robots page.
Head-to-Head Comparison
Amgen maintains a broader therapeutic portfolio and established cash flows that support dividends and share repurchases, contrasting with Biogen’s narrower focus on central nervous system disorders where clinical outcomes can drive sharper sentiment shifts. Recent momentum favors Amgen’s pre-earnings stability, while Biogen has experienced more pronounced reactions to quarterly results and trial updates. Risk factors differ notably: Amgen carries exposure to patent expirations and pricing pressures across multiple franchises, whereas Biogen faces binary events tied to Alzheimer’s and other late-stage assets. Sector exposure overlaps in biotechnology, yet market positioning varies with Amgen’s larger market capitalization providing relative scale and Biogen’s valuation reflecting higher growth optionality in select pipelines. Overall, trade-offs center on diversification versus concentrated upside potential in evolving therapeutic areas.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings visibility, and relative positioning in recent weeks, Tickeron’s AI models currently assign a modest probabilistic edge to AMGN due to steadier operational metrics and upcoming data clarity. This assessment remains subject to change with new information and reflects pattern analysis rather than directional certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileBIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- BIIB’s TA Score: 5 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +6.43% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +3.31% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.46%. For the same industry, the average monthly price growth was +4.50%, and the average quarterly price growth was +4.64%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
BIIB is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.46% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BIIB | AMGN / BIIB | |
| Capitalization | 238B | 32B | 744% |
| EBITDA | 17.6B | 2.14B | 823% |
| Gain YTD | 36.971 | 23.177 | 160% |
| P/E Ratio | 27.29 | 38.50 | 71% |
| Revenue | 38.1B | 10B | 381% |
| Total Cash | 923M | 1.29B | 72% |
| Total Debt | 57.3B | 8.36B | 686% |
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 8 | 100 | |
SMR RATING 1..100 | 47 | 84 | |
PRICE GROWTH RATING 1..100 | 7 | 16 | |
P/E GROWTH RATING 1..100 | 34 | 6 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (8) in the Biotechnology industry is somewhat better than the same rating for BIIB (69). This means that AMGN’s stock grew somewhat faster than BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (47) in the Biotechnology industry is somewhat better than the same rating for BIIB (84). This means that AMGN’s stock grew somewhat faster than BIIB’s over the last 12 months.
AMGN's Price Growth Rating (7) in the Biotechnology industry is in the same range as BIIB (16). This means that AMGN’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (6) in the Biotechnology industry is in the same range as AMGN (34). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 51% | 3 days ago 78% |
| Stochastic ODDS (%) | 3 days ago 48% | 3 days ago 70% |
| Momentum ODDS (%) | 3 days ago 60% | 3 days ago 54% |
| MACD ODDS (%) | 3 days ago 58% | 3 days ago 63% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 59% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 63% |
| Advances ODDS (%) | 6 days ago 60% | 5 days ago 57% |
| Declines ODDS (%) | 21 days ago 50% | 13 days ago 71% |
| BollingerBands ODDS (%) | 3 days ago 52% | 3 days ago 70% |
| Aroon ODDS (%) | 3 days ago 56% | 3 days ago 60% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +1.88% | ||
| BIIB - AMGN | 62% Loosely correlated | +1.13% | ||
| PFE - AMGN | 53% Loosely correlated | +1.01% | ||
| GILD - AMGN | 52% Loosely correlated | +1.87% | ||
| MRK - AMGN | 48% Loosely correlated | +2.39% | ||
| ABBV - AMGN | 48% Loosely correlated | +1.20% | ||
More | ||||